Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.62 |
| ▸ | JAK2 | O60674 | 2/20 | 0.62 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.62 |
| ▸ | SYK | P43405 | 6/20 | 0.61 |
| ▸ | EGFR | P00533 | 9/20 | 0.58 |
| ▸ | BTK | Q06187 | 3/20 | 0.56 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | ITK | Q08881 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1197841 | 0.92 | SYK (0.63) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1196779 | 0.92 | AURKA (0.59) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1135771 | 0.92 | AURKA (0.59) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1197680 | 0.88 | SYK (0.79) | AURKAJAK2AURKBSYKGSK3A | |
| SCHEMBL1196951 | 0.87 | SYK (0.69) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1198221 | 0.85 | AURKA (0.60) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL4003150 | 0.85 | SYK (0.61) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1198269 | 0.84 | SYK (0.65) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1197996 | 0.84 | SYK (0.63) | AURKAJAK2AURKBSYKEGFR | |
| SCHEMBL1198308 | 0.84 | SYK (0.60) | AURKAJAK2AURKBSYKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | claimed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | claimed |
| US-8299087-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110027856-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2011-02-03 | — | — | US | disclosed |
| US-7834024-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2010-11-16 | — | — | US | disclosed |
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008118823-A2 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080260754-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | AURKA 751/4885JAK2 2/4885AURKB 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.